

**Bio-Light has completed raising capital from strategic investors and the public**

**The company had successfully completed the raising of more than 28 million shekels**

**Tel-Aviv, November 5, 2012 - Bio-Light Israeli Life Science Investments (TASE: BOLT)**, pioneering a unique strategy for encouraging innovation in the Life-Science industry, through creation of clusters of companies dealing with a specific medical condition, announced today that it had successfully completed the raising of more than 28 million shekels through share issue at market price to shareholders of the company and other investors. Among the investors are Mr. Israel Makov, the Chairman of Bio-Light, Mr. Dilip Shanghvi, the owner and CEO of Sun Pharmaceutical and Dexcel Pharma, a private company owned by Mr. Dan Oren.

**Suzana Nahum Zilberberg, Bio-Light's CEO:** "The completion of the capital raising, in which strategic investors and other investors were participated, is an expression of trust on the part of shareholders and investors in the company and the unique strategy that the company implements. The amount, which was raised more than 28 million shekels, is extraordinary by the standards of Israeli Biomed field and leads to a quantum leap in the financial capability of Bio-Light to realize its clusters strategy, which will lead to the creation of value for shareholders. In the last year and a half, we have been working on building the operational infrastructure of the company, which includes the cancer diagnostics cluster, managed through Micromedic Technologies (TASE: MCTC), consisting of eight technologies as well as cluster that focuses on eye diseases, with emphasis on glaucoma and dry eye syndrome, held directly by Bio-Light, comprising at this stage, two novel technologies. Today we already see the added value at the level of the cluster's companies, at the level of the clusters themselves and at the level of Bio-Light. Using the raised capital, we shall reinforce and refine our existing clusters and promote investment in new additional clusters".

Today, Bio-Light is involved in two key fields of activity: cancer diagnosis and eye disease.

The cancer diagnostics cluster is targeting an attractive, growing market, with the estimated market size of \$9.5 billion and growing rate of approximately 18% per year. This market is hungry for solutions that can provide early disease diagnosis and personalization of treatments to maximize their efficacy. Consequently, this market attracts the world's major players. Companies in the cluster develop technological solutions for colon, breast, urinary bladder, lung and other cancer indications.

The eye disease cluster, which focuses on glaucoma and dry eye syndrome, is also targeting an attractive market, worth approximately \$8 billion; the market is looking for effective, safe solutions, from the stages of diagnosis and monitoring to medication and surgical solutions. This field is also generating interest among major players in the market. The cluster already includes IOptima, a company which developed an innovative CO<sub>2</sub> laser instrument for non-invasive glaucoma surgery. Another member of the cluster, ViSci is developing an intraocular implant for delayed release of eye drops.

**About Bio-Light:**

Bio-Light Investments in Life Science in Israel Ltd. creates and manages clusters of companies, working within a specific medical field defined for each cluster.

The company was formed in April 2005, and in April 2011 a group of investors headed by Mr. Israel Makov gained control over the company and presented a new strategy of creating value through knowledge sharing (the clusters approach).

Bio-Light has started to apply its unique Biomed clusters' strategy to create synergetic value through the sharing of knowledge between companies that work within shared and contiguous fields of activity. The model is based on a cooperative work, making it possible to deal with a disease from multiple directions: drugs, medical devices, molecular diagnosis, imaging and more, all these under a defined company cluster. Such cooperation creates value by forming a shared knowledge basis and extensive experience to ensure comprehensive familiarity with all aspects of the disease, the market, the competition landscape and the leading players. The cluster approach will lead to development of unique and innovative solutions while being especially beneficial for signing cooperation agreements with leading strategic partners.

For further information, please visit: [www.bio-light.co.il](http://www.bio-light.co.il)